Is there a Bearish outlook for Eleven Biotherapeutics Inc (NASDAQ:EBIO) this week?

August 30, 2017 - By Adrian Mccoy

 Is there a Bearish outlook for Eleven Biotherapeutics Inc (NASDAQ:EBIO) this week?
Investors sentiment decreased to 1 in Q4 2016. Its down 1.29, from 2.29 in 2016Q3. It dropped, as 6 investors sold Eleven Biotherapeutics Inc shares while 5 reduced holdings. 5 funds opened positions while 6 raised stakes. 1.14 million shares or 22.20% more from 933,766 shares in 2016Q3 were reported.
Susquehanna International Grp Llp, a Pennsylvania-based fund reported 15,586 shares. Moreover, Comml Bank Of New York Mellon Corp has 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Kcg invested in 0% or 29,478 shares. Moreover, Blackrock Fund Advisors has 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Oxford Asset Mgmt stated it has 179,627 shares or 0.02% of all its holdings. Blackrock Institutional Trust Na reported 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Northern Trust Corp has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Geode Capital Limited Liability owns 46,887 shares for 0% of their portfolio. Price T Rowe Assocs Md holds 28,200 shares. Fiduciary Tru Company, a Massachusetts-based fund reported 10,000 shares. Royal Natl Bank Of Canada reported 500 shares or 0% of all its holdings. 14,860 were reported by Credit Suisse Ag. Barclays Pcl invested in 0% or 13 shares. Morgan Stanley holds 4,080 shares or 0% of its portfolio. Vanguard Inc holds 121,156 shares or 0% of its portfolio.

Eleven Biotherapeutics Inc (NASDAQ:EBIO) Ratings Coverage

Among 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Eleven Biotherapeutics had 4 analyst reports since August 15, 2015 according to SRatingsIntel. Leerink Swann maintained the shares of EBIO in report on Saturday, August 15 with “Outperform” rating. Leerink Swann downgraded the shares of EBIO in report on Tuesday, January 19 to “Market Perform” rating. The firm has “Neutral” rating given on Tuesday, January 19 by Citigroup. The stock of Eleven Biotherapeutics Inc (NASDAQ:EBIO) earned “Neutral” rating by Citigroup on Wednesday, March 16. Below is a list of Eleven Biotherapeutics Inc (NASDAQ:EBIO) latest ratings and price target changes.

About 50,520 shares traded. Eleven Biotherapeutics Inc (NASDAQ:EBIO) has risen 30.97% since August 30, 2016 and is uptrending. It has outperformed by 14.27% the S&P500.

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The company has market cap of $27.36 million. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. It has a 4.99 P/E ratio. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema and uveitis.

More notable recent Eleven Biotherapeutics Inc (NASDAQ:EBIO) news were published by: Seekingalpha.com which released: “Eleven Bio: Is It Cheap?” on December 29, 2016, also Bostonglobe.com with their article: “Eleven Biotherapeutics buys Canadian company” published on September 21, 2016, Seekingalpha.com published: “Eleven Biotherapeutics’ (EBIO) CEO Stephen Hurly on Q4 2016 Results – Earnings …” on March 24, 2017. More interesting news about Eleven Biotherapeutics Inc (NASDAQ:EBIO) were released by: Businesswire.com and their article: “Eleven Biotherapeutics to Present at Canaccord Genuity 37” published on August 03, 2017 as well as Reuters.com‘s news article titled: “BRIEF-Eleven Biotherapeutics Q2 loss per share $0.30” with publication date: August 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.